Capricor Therapeutics Share Price Today

Capricor Therapeutics Q3FY26 Results: Net loss widens to $42.7M

Net loss widened to $42.7 million in Q3FY26 from $24.6 million YoY. Loss per share of 73 cents missed consensus estimate of 5-cent loss. Shares rose 15.22% to $10.22 despite wider-than-expected results. Cash position stands at $199 million as of September 30, 2026. FDA PDUFA target action date set for November 22, 2026.

Capricor shares fall 9.4% as FDA staff questions deramiocel efficacy

Capricor Therapeutics shares fell 9.39% to $8.11 on Monday following an FDA briefing document stating HOPE-3 data lacks substantial evidence of effectiveness. The FDA staff concluded that Study HOPE-3 results, combined with HOPE-2, do not support deramiocel's efficacy for Duchenne Muscular Dystrophy. Capricor presented open-label extension data showing a 76% reduction in the rate of functional loss for delayed-start patients after switching to therapy. The FDA extended the PDUFA target action date to November 22 to review the amended Biologics License Application focused on upper-limb function preservation.

Capricor investors face Sept 28 deadline in deramiocel fraud suit

Lead plaintiff deadline for Capricor Therapeutics securities class action is September 28, 2026. Stock declined 78.7% ($15.08 per share) after FDA briefing documents disclosed unagreed SAP changes. Allegations include failure to disclose hypersensitivity rates of 42% in treated patients vs 15% placebo. Class period runs from December 17, 2025 to July 26, 2026.

Kaplan Fox joins coalition urging Capricor investors to act by Sept 28

Kaplan Fox & Kilsheimer LLP urges Capricor investors to seek lead plaintiff status by Sept 28, 2026. The firm highlights its history of recovering over $10 billion for clients in securities litigation. Class period covers purchases between Dec 17, 2025, and Jul 26, 2026. Allegations center on undisclosed changes to the statistical analysis plan for the HOPE-3 trial.

FDA extends Capricor deramiocel BLA review to Nov 22 amid class action

FDA extends Capricor deramiocel BLA review to November 22, 2026, after major amendment. Securities class action lawsuit pending with lead plaintiff deadline of September 28, 2026. Stock fell 64.5% in July 2026 following FDA concerns over statistical analysis plan changes. Advisory committee voted 9-3 against efficacy evidence for DMD-associated cardiomyopathy.

Kaos Capital demands Capricor board reset amid soaring costs

Activist Kaos Capital demands immediate board meeting at Capricor Therapeutics. Firm seeks two independent directors and an M&A committee to reduce single-asset risk. Capricor cash fell $80.2 million to $237.9 million as of June 30, 2026. G&A expenses doubled to $23.5 million in H1 2026, prompting calls for cost cuts. Shares dropped 8.92% to $6.22 following the activist letter.